Literature DB >> 21944089

Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.

Baris Turkbey1, Haresh Mani, Vijay Shah, Ardeshir R Rastinehad, Marcelino Bernardo, Thomas Pohida, Yuxi Pang, Dagane Daar, Compton Benjamin, Yolanda L McKinney, Hari Trivedi, Celene Chua, Gennady Bratslavsky, Joanna H Shih, W Marston Linehan, Maria J Merino, Peter L Choyke, Peter A Pinto.   

Abstract

PURPOSE: We determined the prostate cancer detection rate of multiparametric magnetic resonance imaging at 3T. Precise one-to-one histopathological correlation with magnetic resonance imaging was possible using prostate magnetic resonance imaging based custom printed specimen molds after radical prostatectomy.
MATERIALS AND METHODS: This institutional review board approved prospective study included 45 patients (mean age 60.2 years, range 49 to 75) with a mean prostate specific antigen of 6.37 ng/ml (range 2.3 to 23.7) who had biopsy proven prostate cancer (mean Gleason score of 6.7, range 6 to 9). Before prostatectomy all patients underwent prostate magnetic resonance imaging using endorectal and surface coils on a 3T scanner, which included triplane T2-weighted magnetic resonance imaging, apparent diffusion coefficient maps of diffusion weighted magnetic resonance imaging, dynamic contrast enhanced magnetic resonance imaging and spectroscopy. The prostate specimen was whole mount sectioned in a customized mold, allowing geometric alignment to magnetic resonance imaging. Tumors were mapped on magnetic resonance imaging and histopathology. Sensitivity, specificity, positive predictive value and negative predictive value of magnetic resonance imaging for cancer detection were calculated. In addition, the effects of tumor size and Gleason score on the sensitivity of multiparametric magnetic resonance imaging were evaluated.
RESULTS: The positive predictive value of multiparametric magnetic resonance imaging to detect prostate cancer was 98%, 98% and 100% in the overall prostate, peripheral zone and central gland, respectively. The sensitivity of magnetic resonance imaging sequences was higher for tumors larger than 5 mm in diameter as well as for those with higher Gleason scores (greater than 7, p <0.05).
CONCLUSIONS: Prostate magnetic resonance imaging at 3T allows for the detection of prostate cancer. A multiparametric approach increases the predictive power of magnetic resonance imaging for diagnosis. In this study accurate correlation between multiparametric magnetic resonance imaging and histopathology was obtained by the patient specific, magnetic resonance imaging based mold technique.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21944089      PMCID: PMC5540658          DOI: 10.1016/j.juro.2011.07.013

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer.

Authors:  Byung Kwan Park; Bohyun Kim; Chan Kyo Kim; Hyun Moo Lee; Ghee Young Kwon
Journal:  J Comput Assist Tomogr       Date:  2007 Jul-Aug       Impact factor: 1.826

2.  A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

Authors:  Vijay Shah; Thomas Pohida; Baris Turkbey; Haresh Mani; Maria Merino; Peter A Pinto; Peter Choyke; Marcelino Bernardo
Journal:  Rev Sci Instrum       Date:  2009-10       Impact factor: 1.523

3.  Comparative evaluation between external phased array coil at 3 T and endorectal coil at 1.5 T: preliminary results.

Authors:  Pietro Torricelli; Francesco Cinquantini; Guido Ligabue; Giampaolo Bianchi; Pamela Sighinolfi; Renato Romagnoli
Journal:  J Comput Assist Tomogr       Date:  2006 May-Jun       Impact factor: 1.826

4.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study.

Authors:  J Scheidler; H Hricak; D B Vigneron; K K Yu; D L Sokolov; L R Huang; C J Zaloudek; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

5.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.

Authors:  Arnauld Villers; Philippe Puech; Damien Mouton; Xavier Leroy; Charles Ballereau; Laurent Lemaitre
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

6.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.

Authors:  Huadong Miao; Hiroshi Fukatsu; Takeo Ishigaki
Journal:  Eur J Radiol       Date:  2006-11-07       Impact factor: 3.528

7.  MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.

Authors:  Sophie F Riches; Geoffrey S Payne; Veronica A Morgan; Samir Sandhu; Cyril Fisher; Michael Germuska; David J Collins; Alan Thompson; Nandita M deSouza
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

8.  Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection.

Authors:  Andrew B Rosenkrantz; Jeffry Neil; Xiangtian Kong; Jonathan Melamed; James S Babb; Samir S Taneja; Bachir Taouli
Journal:  AJR Am J Roentgenol       Date:  2010-02       Impact factor: 3.959

9.  Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results.

Authors:  Chan Kyo Kim; Byung Kwan Park; Hyun Moo Lee; Ghee Young Kwon
Journal:  Invest Radiol       Date:  2007-12       Impact factor: 6.016

10.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

Authors:  Iclal Ocak; Marcelino Bernardo; Greg Metzger; Tristan Barrett; Peter Pinto; Paul S Albert; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

View more
  169 in total

1.  Prototype Design and Phantom Evaluation of a Device for Co-registered MRI/TRUS Imaging of the Prostate.

Authors:  Andriy Fedorov; Sang-Eun Song; Tina Kapur; Robert Owen; Emily Neubauer Sugar; Paul Nguyen; William M Wells; Clare M Tempany
Journal:  Clin Image Based Proced       Date:  2014

Review 2.  Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 3.  [Multiparametric MRI, elastography, contrastenhanced TRUS. Are there indications with reliable diagnostic advantages before prostate biopsy?].

Authors:  A Hegele; L Skrobek; R Hofmann; P Olbert
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 4.  Image guidance in the focal treatment of prostate cancer.

Authors:  Anthony N Hoang; Dmitry Volkin; Nitin K Yerram; Srinivas Vourganti; Jeffrey Nix; W Marston Linehan; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

Review 5.  [Multiparametric imaging with simultaneous MRI/PET: Methodological aspects and possible clinical applications].

Authors:  S Gatidis; H Schmidt; C D Claussen; N F Schwenzer
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

Review 6.  Prostate biopsy for the interventional radiologist.

Authors:  Cheng William Hong; Hayet Amalou; Sheng Xu; Baris Turkbey; Pingkun Yan; Jochen Kruecker; Peter A Pinto; Peter L Choyke; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2014-02-26       Impact factor: 3.464

7.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

8.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Authors:  Berrend G Muller; Jurgen J Fütterer; Rajan T Gupta; Aaron Katz; Alexander Kirkham; John Kurhanewicz; Judd W Moul; Peter A Pinto; Ardeshir R Rastinehad; Cary Robertson; Jean de la Rosette; Rafael Sanchez-Salas; J Stephen Jones; Osamu Ukimura; Sadhna Verma; Hessel Wijkstra; Michael Marberger
Journal:  BJU Int       Date:  2013-11-13       Impact factor: 5.588

9.  Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer.

Authors:  Soroush Rais-Bahrami; Baris Turkbey; Kinzya B Grant; Peter A Pinto; Peter L Choyke
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

10.  Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy.

Authors:  Sandeep Sankineni; Arvin K George; Anna M Brown; Soroush Rais-Bahrami; Bradford J Wood; Maria J Merino; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Abdom Imaging       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.